Utrogestan® is progesterone with proven safety for mother and fetus

Authors

  • А. Г. Резников V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine
  • С. Н. Занько Belarusian Medical Association “Reproductive Health”, Vitebsk, Belarus

DOI:

https://doi.org/%20

Keywords:

bioidentical micronized progesterone, Utrogestan, premature labor, pregnancy preservation

Abstract

According to official data of the European Society of Human Reproduction and Embryology, 15–17% of married couples suffer from infertility in Ukraine. This in combination with the tendency towards late maternity makes it increasingly common to use assisted reproductive technologies for the infertility problem. No less relevant is the spontaneous abortions and miscarriage problem, one cause of which is the insufficient progesterone production by the corpus luteum and placenta, along with other factors. The article discusses the use of the drug Utrogestan®, bioidentical micronized progesterone in the form of soft capsules for intravaginal and oral administration in assisted reproductive technology programs and in the management and pregnancy preserving.

Progesterone plays an important role in the ovarian-menstrual cycle regulation, secretory transformation of the endometrium, pregnancy preservation, regulation of sexual behavior and other physiological processes. In Ukraine, Utrogestan® is allowed to be used in pregravid preparation (partial or complete insufficiency of the luteal phase), to support the luteal phase in induced and spontaneous menstrual cycles, in insemination programs and in vitro fertilization, in cases of miscarriage, for the prevention of habitual miscarriages and premature labor in women with a short cervix or a history of preterm labor. Not all micronized progesterone drugs registered in Ukraine have similar indications, in particular for the prevention of preterm birth in women with a short cervix and premature labor in history. According to the medical instruction, Utrogestan® is allowed to be used throughout the entire gestation period up to the 36th week of pregnancy, which ensures continuity of treatment. Only natural/bioidentical progesterone is a substrate for reduced 5-α and 5-β-metabolites that have a specific effect during pregnancy. Utrogestan® is characterized by high safety for mother and fetus, as well as good local and systemic tolerance.

Author Biographies

А. Г. Резников, V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv

MD, professor, academician of the NAMS of Ukraine, corresponding member of the NAS of Ukraine, Head of Endocrinology of Reproduction and Adaptation Department

С. Н. Занько, Belarusian Medical Association “Reproductive Health”, Vitebsk

MD, professor, chairman of the Board

Downloads

Published

2019-05-21

How to Cite

Резников, А. Г., & Занько, С. Н. (2019). Utrogestan® is progesterone with proven safety for mother and fetus. REPRODUCTIVE ENDOCRINOLOGY, (46), 62–67. https://doi.org/

Issue

No. 46 (2019)

Section

Drug therapy

License

Copyright (c) 2019 А. Г. Резников, С. Н. Занько

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.